company background image
EQL logo

EQL Pharma OM:EQL Voorraadrapport

Laatste prijs

SEK 69.40

Marktkapitalisatie

SEK 2.0b

7D

10.2%

1Y

100.6%

Bijgewerkt

26 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

EQL Pharma AB (publ)

OM:EQL Voorraadrapport

Marktkapitalisatie: SEK 2.0b

EQL Overzicht aandelen

EQL Pharma AB (publ) houdt zich bezig met de ontwikkeling, marketing en verkoop van generieke geneesmiddelen aan apotheken en ziekenhuizen in Zweden, Denemarken, Noorwegen, Finland en de rest van Europa. Meer informatie

Beloningen

Verhandeld tegen 54.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 53.34% per jaar groeien

De winst is de afgelopen 5 jaar met 30.5% per jaar gegroeid

Risicoanalyse

De schulden worden niet goed gedekt door de operationele kasstroom

Hoog niveau van niet-contante inkomsten


EQL Pharma AB (publ) Concurrenten

Humana

OM:HUM

SEK 1.9b

Dedicare

OM:DEDI

SEK 569.0m

Ambea

OM:AMBEA

SEK 7.9b

Stille

OM:STIL

SEK 1.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor EQL Pharma
Historische aandelenkoersen
Huidige aandelenkoersSEK 69.40
52 Week HoogtepuntSEK 69.60
52 Week LaagSEK 32.10
Bèta0.62
11 maand verandering8.78%
3 maanden verandering24.37%
1 Jaar Verandering100.58%
33 jaar verandering104.72%
5 jaar verandering421.80%
Verandering sinds IPO1,096.55%

Recent nieuws en updates

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Recent updates

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Rendement voor aandeelhouders

EQLSE HealthcareSE Markt
7D10.2%2.1%0.5%
1Y100.6%35.4%12.3%

Rendement versus industrie: EQL overtrof de Swedish Healthcare industrie, die het afgelopen jaar een rendement 35.4 % opleverde.

Rendement versus markt: EQL overtrof de Swedish markt, die het afgelopen jaar een rendement opleverde van 12.3 %.

Prijsvolatiliteit

Is EQL's price volatile compared to industry and market?
EQL volatility
EQL Average Weekly Movement4.9%
Healthcare Industry Average Movement4.0%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.4%
10% least volatile stocks in SE Market3.3%

Stabiele aandelenkoers: EQL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van EQL is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
200620Axel Schorlingwww.eqlpharma.com

EQL Pharma AB (publ) houdt zich bezig met de ontwikkeling, marketing en verkoop van generieke geneesmiddelen aan apotheken en ziekenhuizen in Zweden, Denemarken, Noorwegen, Finland en de rest van Europa. Het biedt injectieproducten voor intramurale zorg en formuleringen voor ambulante zorg. EQL Pharma AB (publ) werd opgericht in 2006 en is gevestigd in Lund, Zweden.

EQL Pharma AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van EQL Pharma zich tot de beurswaarde?
EQL fundamentele statistieken
MarktkapitalisatieSEK 2.02b
Inkomsten(TTM)SEK 31.18m
Inkomsten(TTM)SEK 316.38m

64.7x

Koers/Winstverhouding

6.4x

P/S-verhouding

Is EQL overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EQL resultatenrekening (TTM)
InkomstenSEK 316.38m
Kosten van inkomstenSEK 179.73m
BrutowinstSEK 136.66m
Overige uitgavenSEK 105.48m
InkomstenSEK 31.18m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 05, 2025

Winst per aandeel (EPS)1.07
Brutomarge43.19%
Nettowinstmarge9.85%
Schuld/Eigen Vermogen Verhouding74.9%

Hoe presteerde EQL op de lange termijn?

Bekijk historische prestaties en vergelijking